
Dec 7, 2012
Back in January, Cambridge, MA, cancer therapeutic developer Verastem ($VSTM) made its initial public offering (IPO) and raised $55M in the process. It was not a monumental IPO success by biopharma standards, but what made the event noteworthy was that Verastem hadn’t yet filed an IND for its lead drug candidate, the first step in the FDA regulatory process...